An Epidemiological Prospective Cohort Study to Describe Treatment Patterns of Fulvestrant And ExemeSTane in Postmenopausal Patients With Advanced HR+ Breast Cancer Under Real-life Conditions in GERmany

Inclusion Criteria:

- Signed written informed consent

- Female postmenopausal patient (or patient post-ovarectomy) and age ≥18 years
Postmenopause ist defined as

- Age ≥ 60 years and natural menopause with menses > 1year ago or

- FSH and E2 levels in the postmenopausal range or

- Patients who had bilateral ovariectomy (NCCN V.I. 2009)

- Histologically confirmed ER+ locally advanced or metastatic breast cancer

- Not eligible for curative therapy

- Prior treatment with tamoxifen

- Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI

- Patient is able to read and understand German

Exclusion Criteria:

- Known hypersensitivity to Faslodex or Exemestan or any compounds of the drugs

- Prior treatment with Faslodex 500 mg or Faslodex 250 mg*

- for patients who receive treatment with Faslodex 500 mg within this
observational study. Patients who are included in the exemestane arm may have
received prior Faslodex treatment.

- Prior treatment with Exemestan for patients who receive treatment with Exemestan
within this observational study

- Acutely life threatening disease

- Treatment with Faslodex 250 mg/month (previously approved dose)

- Prior palliative chemotherapy